IL17RA and systemic sclerosis: Brodalumab is an effective IL‐17RA antagonist approved for treatment against severe psoriasis.[52] The effectiveness of Brodalumab in SSc has not been definitively established, and our research demonstrates an obvious inhibitory effect of Brodalumab on Chi3L1‐induced fibroblast activation.